Draft:National Resilience

National Resilience, operating primarily as Resilience, is a biomanufacturing and biotechnology company that develops gene therapy, vaccines, viral vectors and other therapeutic protein products. It is headquartered in San Diego, California and has nine additional manufacturing facilities open or in development, including in Missisauga, Boston, the San Francisco Bay Area, North Carolina, Philadelphia, and northern Florida.

Resilience was founded to address problems identified in the private sector during the COVID-19 pandemic in the United States, with the intention to strengthen medical supply chains. The company works with the Government of Canada and United States Department of Defense, as well as a range of biotechnology companies and universities.

Resilience is a member of the Alliance for Regenerative Medicine and Biotechnology Innovation Organization (BIO).

Conception and founding
The idea for Resilience is described as having originated from discussions between ARCH Venture Partners co-founder Robert Nelson and Luciana Borio, then-Vice President of In-Q-Tel, the venture capital firm of the Central Intelligence Agency.

Resilience launched in November 2020 under the leadership of Rahul Singhvi (of Flagship Pioneering, Novavax and Takeda Vaccines) and Nelsen. It received significant seed funding from ARCH and 8VC, beginning operations with a total of $800 million in capital. Former Food and Drug Administration commissioner Scott Gottlieb was brought on to Resilience's board of directors, as was Patrick Wang, former executive vice president at Genentech.

Rapid expansion
In March 2021, Resilience acquired a 310,000 square foot manufacturing facility from Sanofi, formerly used for its Genzyme business. The facility is located on land owned by Harvard University in Boston, Massachessets. Additionally, the company purchased a second location in Mississauga, Ontario, Canada, measuring 136,000 square feet, and took over a Bluebird bio site in North Carolina. In April 2021, Resilience acquired Ology Bioservices. Ology had been awarded a contract in February 2020 from the United States Government to develop an advanced monoclonal antibody therapy against COVID-19.

In May 2021, the Government of Canada announced a CAD $200 million investment in Resilience's Mississauga operation, Resilience Biotechnologies. The City of Mississauga issued a statement in support of the investment, emphasizing that the federal funding would allow the company to manufacture 112 to 640 million doses of mRNA vaccines annually and strengthen the country's ability to respond to future pandemics.

In September 2021, Moderna announced that Resilience would manufacture the synthetic mRNA components of its mRNA-1273 COVID-19 vaccine for delivery worldwide, including its newer "bivalent" product.

In June 2022, Resilience announced it had raised an additional $625 million in funding from undisclosed investors. In March 2023, the company received $410 million in debt financing from the United States Department of Defense and the U.S. International Development Finance Corporation.

On February 5, 2024, Resilience announced a partnership with Taiwan Bio-Manufacturing Corporation (TBMC) to construct a research and manufacturing facility. Resilience received an undisclosed ownership stake in TBMC as part of the deal.

Organization
Reliance's leadership is primarily made up of current and former pharmaceutical executives, politicians, regulatory officials, and venture capitalists. It additionally employs advisors including Mark McClellan, former commissioner of the Food and Drug Administration.

Executive Team

 * Rahul Singhvi - Co-founder and Chief Executive Officer
 * Sandy Mahatme - President, Chief Operating and Financial Officer
 * Viet Nguyen - Chief Manufacturing Officer
 * Syed T. Husain - Chief Commercial Officer
 * Rich Stoner - Chief Scientific Officer
 * Elliot Menschik - Chief Digital Officer
 * Ori Solomon - Chief Legal Officer
 * Mara Strandlund - Chief People Officer
 * Alex Szidon - Chief Business Officer

Board of Directors

 * Robert Nelsen - Chairman, founder
 * Patrick Yang - Vice-chairman
 * Frances Arnold
 * George S. Barrett
 * Mitchell E. Daniels, Jr.
 * Chris Darby
 * Susan Desmond-Hellmann
 * Kate Foster
 * Scott Gottlieb
 * Joseph Robert Kerrey
 * Drew Oetting
 * Denice Torres

Investors
Investors in Resilience include 8VC, Arch Venture Partners, GV (the venture capital arm of Alphabet Inc.) and New Enterprise Associates.

Clients
Resilience's clientele includes pharmaceutical and biotechnology companies, United States government agencies, and academic institutions.

The company works with Takeda Pharmaceutical Company's plasma-derived therapies unit, and manufactures Opus Genetics' gene therapies for inherited renal diseases. Bluebird bio partnered with the company in order to accelerate its cell therapy portfolio.

Its work with the United States Department of Defense includes manufacturing their monoclonal antibody therapy against botulinum neurotoxins.

Its academic collaborators include the Children's Hospital of Philadelphia, Harvard University, and the MD Anderson Cancer Center.